Discover more from FarmaKology’s Substack
FarmaKology Newsletter - Issue #1
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Sanofi’s type I diabetes drug, Zynquista (sotagliflozin).
Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous T-cell lymphoma (CTCL).
Biogen and Eisai have stopped two global Phase III trials of the Alzheimer's drug aducanumab, after interim analyses indicated that the agent was ineffective and would not meet the primary endpoint.
The settlement resolves about 25,000 lawsuits, which claimed the companies failed to warn about deadly bleeding episodes caused by the drug.
Hear from 2019 Guild Pharmacy of the Year finalist, Emerald Plaza Pharmacy owner Jessica Burrey who has a vision to create a health hub to service the community and collaborate with the wider health sector.